Showing 15 posts of 35 posts found.


FDA approves first three generic versions of Novartis’ Gilenya for relapsing multiple sclerosis

December 6, 2019
Medical Communications, Sales and Marketing Novartis, generics, gilenya, multiple sclerosis, pharma

The FDA has approved the first three generic versions of Novartis’ sphingosine 1-phosphate receptor modulator Gilenya (fingolimod) to treat adult …


A decade after US approval, Novartis’ Gilenya scores marketing authorisation in China for relapsing multiple sclerosis

July 19, 2019
Medical Communications, Sales and Marketing Novartis, gilenya, multiple sclerosis, pharma

Novartis has revealed that its disease modifying drug Gilenya (fingolimod) has secured approval in China for the treatment of relapsing …


FDA awards first paediatric MS approval to Novartis’ Gilenya

May 14, 2018
Sales and Marketing FDA, gilenya, multiple sclerosis, pharma

The FDA has awarded approval for what it says is its first drug for the treatment of multiple sclerosis (MS) …


Novartis celebrates success of Gilenya in paediatric multiple sclerosis

September 5, 2017
Manufacturing and Production, Research and Development MS, Novartis, gilenya, health, multiple sclerosis, pharma, pharmaceuticals

Novartis has announced results of its Phase 3 study investigating the safety and efficacy of Gilenya (fingolimod) , finding that …


EMA adds warning label to Novartis’ MS treatment Gilenya

December 22, 2015
Manufacturing and Production EMA, European Medicines Agency, FDA, Novartis, PML, basal cell carcinoma, fingolimod, gilenya

Drug safety regulators in Europe have said they will add warnings to the label and prescribing information of Gilenya (fingolimod), …


Novartis looks to new measure of Gilenya outcomes

October 8, 2015
Research and Development fingolimod, gilenya, multiple sclerosis, relapsing multiple sclerosis

Novartis says a new analysis from two Phase III trials reinforces the long-term efficacy profile of its MS treatment Gilenya. …

Novartis MS drug scores positive late-stage trial result

April 21, 2015
Research and Development, Sales and Marketing MS, Novartis, fingolimod, gilenya, multiple sclerosis

People with some of the most common forms of multiple sclerosis (MS) who are treated with Gilenya are less likely …

Novartis image

Novartis to highlight Gilenya data at neurology congress

April 13, 2015
Sales and Marketing American Academy of Neurology, Novartis, fingolimod, gilenya

Novartis will be highlighting data for its multiple sclerosis drug Gilenya at this year’s American Academy of Neurology (AAN) annual …

Biogen Idec logo

NICE final ‘yes’ for Biogen’s MS pill

August 27, 2014
Sales and Marketing Aubagio, Biogen, RMS, RRMS, gilenya

In final guidance published today NICE has recommended NHS funding of Biogen Idec’s new multiple sclerosis pill in patients with …

Biogen Idec image

Biogen Idec’s MS drug gets European approval

February 4, 2014
Manufacturing and Production, Sales and Marketing Aubagio, Biogen IDEC, EU, MS, gilenya, tecdifera

Biogen Idec’s oral multiple sclerosis drug Tecfidera has won approval in Europe as a first-line treatment for people with relapsing-remitting …

Sales rise for Novartis

January 30, 2014
Sales and Marketing Gleevec, Glivec, Novartis, gilenya, q4, sales

Multiple sclerosis drug Gilenya, with sales rising 62% year-on-year to $1.9 billion, was one of the stars of last year …

Aubagio image

NICE recommends Aubagio

January 22, 2014
Sales and Marketing Aubagio, EU, FDA, NICE, Sanofi, gilenya

NICE has recommended Genzyme’s multiple sclerosis pill Aubagio for use on the NHS. In final guidance the watchdog said Aubagio …

biogen idec image

Strong sales for Biogen Idec’s MS drug

October 29, 2013
Sales and Marketing Biogen IDEC, Q3, gilenya, tecfidera

Biogen Idec’s oral multiple sclerosis (MS) drug Tecfidera lived up to its blockbuster-in-waiting billing with third quarter sales that exceeded …

Novartis image

Novartis sees profit slip

October 23, 2013
Sales and Marketing Afinitor, Diovan, Novartis, Q3, gilenya

Novartis saw generic competition erode profit in the third quarter of the year, although sales across the group actually rose …

Latest content